Sector
PharmaceuticalsOpen
₹48Prev. Close
₹46.83Turnover(Lac.)
₹0.45Day's High
₹48Day's Low
₹4652 Week's High
₹55.0252 Week's Low
₹25.03Book Value
₹-2.16Face Value
₹10Mkt Cap (₹ Cr.)
17.21P/E
0EPS
0Divi. Yield
017 Sep 2024
12:00 AM
BookCloser
6 Feb 2025
12:00 AM
Board Meeting
Agenda : Audited Result
17 Sep 2024
12:00 AM
AGM
Announcement Date: 17 Sep, 2024
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 4.45 | 4.45 | 4.45 | 4.45 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -4.38 | 1.4 | 1.51 | 1.37 |
Net Worth | 0.07 | 5.85 | 5.96 | 5.82 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Revenue | 20.91 | 11.9 | 0 | 0 |
yoy growth (%) | 75.77 | 0 | 0 | |
Raw materials | -11.26 | -5.78 | 0 | 0 |
As % of sales | 53.85 | 48.57 | 0 | 0 |
Employee costs | -2.91 | -2.13 | -0.01 | 0 |
| Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Profit before tax | 0.73 | 0 | 0 | 0.01 |
Depreciation | -1 | -1.09 | 0 | 0 |
Tax paid | -0.3 | 0 | -0.01 | -0.01 |
Working capital | -0.24 | -2.57 | 0.01 | |
Other operating items |
| Y/e 31 Mar | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 75.77 | 0 | 0 | |
Op profit growth | 63.49 | -2,069.75 | 12.91 | |
EBIT growth | 2,335.31 | 587.94 | -55.19 | |
Net profit growth | 78,904.6 | -106.88 | 108.03 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,744.85 | 132.89 | 4,18,647.96 | 1,181.05 | 0.77 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,001.1 | 76.85 | 1,59,310.35 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,478.5 | 25.66 | 1,19,409.63 | 1,438.15 | 0.88 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,137.55 | 58.21 | 1,06,184.18 | 485 | 0.89 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,413.35 | 51.49 | 99,569.64 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Umang Alkesh Gosalia
Non-Exec. & Independent Dir.
Ami R Shah
Non-Exec. & Independent Dir.
Nikhil S. Uchat
Company Sec. & Compli. Officer
Bhakti Rameshbhai Aghera
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Parmax Pharma Ltd
Summary
Incorporated in Nov.94, Parmax Pharma Ltd (PPL) was promoted by Jayantilal S Dhol, Purushottam J Bhalodi and Prabhudas D Hansalpara. The Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations ( CMO) business are the key pillar of Parmaxs pharmaceutical operations. The Promoters were earlier into manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc. The Company then discontinued their business activities for few years due to various reasons. Starting from their journey as a bulk drug manufacturer and speciality chemicals in 1994; the Company had set up a plant to manufacture and market bulk drugs like amoxycillin tri-hydrate, ampicillin tri-hydrate, cephalexin mono hydrate and nalidixic acid, at Hadamtala, Gujarat, with an installed capacity of 96 TPA. Antibiotic project was fully implemented from 31st May97.
Read More
What is the Parmax Pharma Ltd share price today?
The Parmax Pharma Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹46 today.
What is the Market Cap of Parmax Pharma Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Parmax Pharma Ltd is ₹17.21 Cr. as of 09 May ‘25
What is the PE and PB ratio of Parmax Pharma Ltd?
The PE and PB ratios of Parmax Pharma Ltd is 0 and -21.65 as of 09 May ‘25
What is the 52 Week High and Low of Parmax Pharma Ltd?
The 52-week high/low is the highest and lowest price at which a Parmax Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Parmax Pharma Ltd is ₹25.03 and ₹55.02 as of 09 May ‘25
What is the CAGR of Parmax Pharma Ltd?
Parmax Pharma Ltd's CAGR for 5 Years at 16.00%, 3 Years at 8.32%, 1 Year at 60.38%, 6 Month at -3.34%, 3 Month at -2.42% and 1 Month at 4.77%.
What is the shareholding pattern of Parmax Pharma Ltd?
The shareholding pattern of Parmax Pharma Ltd is as follows:
Promoters - 30.80 %
Institutions - 0.00 %
Public - 69.20 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
